NZ258684A - Vaccine against group b streptococcus comprising a group b streptococcus polysaccharide conjugated to a functional derivative of group b streptococcus c protein alpha antigen - Google Patents
Vaccine against group b streptococcus comprising a group b streptococcus polysaccharide conjugated to a functional derivative of group b streptococcus c protein alpha antigenInfo
- Publication number
- NZ258684A NZ258684A NZ258684A NZ25868493A NZ258684A NZ 258684 A NZ258684 A NZ 258684A NZ 258684 A NZ258684 A NZ 258684A NZ 25868493 A NZ25868493 A NZ 25868493A NZ 258684 A NZ258684 A NZ 258684A
- Authority
- NZ
- New Zealand
- Prior art keywords
- sequence
- group
- streptococcus
- protein
- seq
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6068—Other bacterial proteins, e.g. OMP
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US96886692A | 1992-11-02 | 1992-11-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
NZ258684A true NZ258684A (en) | 1997-04-24 |
Family
ID=25514876
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NZ258684A NZ258684A (en) | 1992-11-02 | 1993-11-02 | Vaccine against group b streptococcus comprising a group b streptococcus polysaccharide conjugated to a functional derivative of group b streptococcus c protein alpha antigen |
Country Status (14)
Country | Link |
---|---|
EP (1) | EP0669985A1 (fi) |
JP (1) | JPH08505282A (fi) |
KR (1) | KR100349331B1 (fi) |
AU (1) | AU689452B2 (fi) |
CA (1) | CA2146926A1 (fi) |
FI (1) | FI951979A (fi) |
HU (1) | HU220198B (fi) |
IL (1) | IL107458A0 (fi) |
NO (1) | NO951629L (fi) |
NZ (1) | NZ258684A (fi) |
PL (1) | PL177302B1 (fi) |
RU (1) | RU2209247C2 (fi) |
WO (1) | WO1994010317A2 (fi) |
ZA (1) | ZA938171B (fi) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6015889A (en) * | 1993-03-19 | 2000-01-18 | Gunnar Lindahl | Protein rib, a cell surface protein that confers immunity to many strains of the group B streptococcus: process for purification of the protein, reagent kit and pharmaceutical composition |
US6284884B1 (en) | 1995-06-07 | 2001-09-04 | North American Vaccine, Inc. | Antigenic group B streptococcus type II and type III polysaccharide fragments having a 2,5-anhydro-D-mannose terminal structure and conjugate vaccine thereof |
US6426074B1 (en) * | 1997-03-19 | 2002-07-30 | The Brigham And Women's Hospital Inc. | Group B Streptococcus vaccine |
US7098182B2 (en) | 1998-07-27 | 2006-08-29 | Microbial Technics Limited | Nucleic acids and proteins from group B streptococcus |
JP2002531054A (ja) * | 1998-07-27 | 2002-09-24 | マイクロビアル テクニクス リミティッド | B群連鎖球菌由来の核酸およびタンパク質 |
US6890539B2 (en) | 1998-12-22 | 2005-05-10 | Microscience, Ltd. | Genes and proteins, and their use |
KR100818815B1 (ko) * | 1998-12-22 | 2008-04-01 | 마이크로싸이언스 리미티드 | 외표면 단백질들, 그들의 유전자들 및 그들의 사용 |
GB9910375D0 (en) | 1999-05-05 | 1999-06-30 | Lindahl Gunnar | Vaccine composition |
ES2382893T3 (es) * | 2000-10-13 | 2012-06-14 | Id Biomedical Corporation | Antígenos BVH-A2 y BVH-3 de streptococcus del grupo B |
WO2004080490A2 (en) * | 2003-03-07 | 2004-09-23 | Wyeth Holdings Corporation | Polysaccharide - staphylococcal surface adhesin carrier protein conjugates for immunization against nosocomial infections |
PL2144924T3 (pl) | 2007-04-16 | 2017-06-30 | Minervax Aps | Szczepionka z białkiem fuzyjnym |
CA2734340C (en) | 2008-08-28 | 2019-03-05 | Novartis Ag | Cell surface display of polypeptide isoforms by stop codon readthrough |
CA3001433A1 (en) | 2015-10-21 | 2017-04-27 | Minervax Aps | Immunogenic fusion protein |
CA3004631A1 (en) | 2015-12-30 | 2017-07-06 | Minervax Aps | Immunogenic complex for eliciting protective immunity against group b streptococcus |
CA3066020A1 (en) | 2017-06-16 | 2018-12-20 | Glaxosmithkline Biologicals Sa | Method of treatment |
CA3161857A1 (en) | 2019-11-22 | 2021-05-27 | Glaxosmithkline Biologicals Sa | Dosage and administration of a bacterial saccharide glycoconjugate vaccine |
EP4066854A1 (en) | 2021-03-29 | 2022-10-05 | MinervaX | Immunogenic fusion protein |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0302887B1 (en) * | 1986-04-16 | 1994-06-22 | The Brigham And Women's Hospital, Inc. | Bacterial antigens, antibodies, vaccines, and methods of manufacture |
IL95578A (en) * | 1989-09-15 | 1998-08-16 | Gen Hospital Corp | A vaccine made from polysaccharide and protein |
-
1993
- 1993-11-01 IL IL10745893A patent/IL107458A0/xx unknown
- 1993-11-02 ZA ZA938171A patent/ZA938171B/xx unknown
- 1993-11-02 EP EP94902202A patent/EP0669985A1/en not_active Withdrawn
- 1993-11-02 WO PCT/US1993/010506 patent/WO1994010317A2/en not_active Application Discontinuation
- 1993-11-02 PL PL93308555A patent/PL177302B1/pl not_active IP Right Cessation
- 1993-11-02 AU AU56654/94A patent/AU689452B2/en not_active Ceased
- 1993-11-02 RU RU95113472/13A patent/RU2209247C2/ru not_active IP Right Cessation
- 1993-11-02 CA CA002146926A patent/CA2146926A1/en not_active Abandoned
- 1993-11-02 JP JP6511389A patent/JPH08505282A/ja active Pending
- 1993-11-02 KR KR1019950701811A patent/KR100349331B1/ko not_active IP Right Cessation
- 1993-11-02 HU HU9501260A patent/HU220198B/hu not_active IP Right Cessation
- 1993-11-02 NZ NZ258684A patent/NZ258684A/en unknown
-
1995
- 1995-04-26 FI FI951979A patent/FI951979A/fi not_active Application Discontinuation
- 1995-04-28 NO NO951629A patent/NO951629L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
JPH08505282A (ja) | 1996-06-11 |
AU689452B2 (en) | 1998-04-02 |
EP0669985A1 (en) | 1995-09-06 |
PL308555A1 (en) | 1995-08-21 |
KR950704492A (ko) | 1995-11-20 |
FI951979A0 (fi) | 1995-04-26 |
WO1994010317A3 (en) | 1994-07-07 |
HUT70981A (en) | 1995-11-28 |
FI951979A (fi) | 1995-06-29 |
WO1994010317A2 (en) | 1994-05-11 |
NO951629L (no) | 1995-07-03 |
RU2209247C2 (ru) | 2003-07-27 |
NO951629D0 (no) | 1995-04-28 |
ZA938171B (en) | 1995-03-07 |
PL177302B1 (pl) | 1999-10-29 |
KR100349331B1 (ko) | 2003-01-06 |
IL107458A0 (en) | 1994-02-27 |
CA2146926A1 (en) | 1994-05-11 |
AU5665494A (en) | 1994-05-24 |
HU220198B (hu) | 2001-11-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6342223B1 (en) | Immunogenic composition for group B Streptococcus | |
AU689452B2 (en) | Conjugate vaccine against group B streptococcus | |
EP0571538B1 (en) | Structural gene of pneumococcal protein | |
US6426074B1 (en) | Group B Streptococcus vaccine | |
AU693175B2 (en) | Epitopic regions of pneumococcal surface protein A | |
EP0491865B1 (en) | Conjugate vaccine for group b streptococcus | |
PL186847B1 (pl) | Konstrukcja DNA, wektor ekspresyjny, gospodarz, białko fuzyjne i sposób przygotowania bakterii | |
AU722078B2 (en) | Conjugate vaccine against group B Streptococcus |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RENW | Renewal (renewal fees accepted) |